首页> 美国卫生研究院文献>Iranian Journal of Pharmaceutical Research : IJPR >Design and Synthesis of Novel 1-hydroxy-245-triaryl Imidazole Derivatives as Anti-cytokine Agents
【2h】

Design and Synthesis of Novel 1-hydroxy-245-triaryl Imidazole Derivatives as Anti-cytokine Agents

机译:作为抗细胞因子剂的新型1-羟基-245-三芳基咪唑衍生物的设计与合成

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Among recent advances in the identification of anti-inflammation agents, anti-cytokines (like Interleukin-1), related to p38 MAPK families play an important role; Here in we designed new effective and low toxic anti-cytokine agents based on 1-hydroxy-2,4,5-triaryl imidazole derivatives. The reaction of oximoinoketone intermediate with ten different aromatic aldehyde and ammonium acetate in refluxing acetic acid condition give imidazole derived product, the IL-1β inhibitory assay were performed on Human PBMCs (peripheral blood mononuclear cells) using an enzyme-linked immunosorbent assay (ELISA) kit and then in computational part the binding mode of the best compound was accomplished by docking in Crystal structure of p38 MAP kinase (PDB ID: 1A9U) compared with SB202190 as standard drug. All compounds were synthesized and evaluated in biological assay showing the inhibitory activity from 28% to 82% compared to SB202190 and binding mode analysis revealed that the hydrogen-bond interactions with residues (Met109, Val30) were key point in inhibitor binding. Compound clearly proved the best inhibitory action and could be further utilized for designing newer anti-cytokine agents and p38α MAP kinase potentially inhibitory action.
机译:在鉴定抗炎剂的最新进展中,抗细胞因子(如白细胞介素-1),与P38 Mapk家族有关的重要作用;在我们设计基于1-羟基-2,4,5-三芳基咪唑衍生物的新的有效和低毒的抗胞嘧啶剂。氧昔单抗中间体用十种不同的芳香族醛和乙酸铵反转乙酸条件的反应得到咪唑衍生产物,使用酶联免疫吸附试验(ELISA)对人PBMC(外周血单核细胞)进行IL-1β抑制测定试剂盒然后在计算部分中,通过作为标准药物的SB202190的P38 MAP激酶(PDB ID:1A9U)的晶体结构对接完成最佳化合物的结合模式。与SB202190相比,在生物测定中合成并评估所有化合物,并在28%至82%的生物测定中评价,结合模式分析显示与残基(MET109,VAL30)的氢键相互作用是抑制剂结合的关键点。化合物清楚地证明了最佳的抑制作用,并且可以进一步用于设计较新的抗细胞因子药物和P38α地图激酶可能抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号